期刊文献+

2015年髓系肿瘤研究进展 被引量:1

Research advances of myeloid neoplasmas in 2015
下载PDF
导出
摘要 本文主要介绍2015年髓系肿瘤的研究进展。包括急性髓系白血病(Acute myeloid leukemia,AML)的分子靶向治疗的研究进展;骨髓增生异常综合征(Myelodysplastic syndrome,MDS)新的分型建议、精准诊断和预后分层以及治疗进展;原发骨髓纤维化(Primary myelofibrosis,PMF)的预后分类系统以及治疗策略。 The research advances of myeloid neoplasms in 2015 will be introduced,such as new molecularly targeted therapies for acute myeloid leukemia(AML),reclassifying myelodysplastic syndromes(MDS),precise diagnosis and risk assessment of MDS,novel therapeutic approaches of MDS,refining risk stratification and treatment strategy in primary myelofibrosis.
出处 《临床荟萃》 CAS 2016年第2期151-155,共5页 Clinical Focus
关键词 白血病 髓样 骨髓增生异常综合征 原发性骨髓纤维化 分子靶向治疗 leukemia myeloid myelodysplastic syndromes primary myelofibrosis molecularly targeted therapy
  • 相关文献

参考文献36

  • 1Burnett A,Wetzler M, Lowenherg B. Therapeutic advances in acute myeloid leukemia[J]. J Clin Oncol, 2011,29 (5) : 487494.
  • 2Dombret H, Seymcur JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with:>30~ blasts[J]. Blood,2015,126(3) :291-299.
  • 3Levis M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013 [J] Hematology AM Soc Hematol Educ Program,2013,2013(1) :220-226.
  • 4Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status[J]. J Clin Onco1,2013,31(29) :3681-3687.
  • 5Levis MJ, Perl AE, Dombret H, et al. Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib(AC220) in patients with FLT3 ITD positive or negtive relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation[C]. ASH Annual Meeting Abstracts,2012,120 (21) :Abstract 673.
  • 6Cortes JE,Perl AE,Dombret H,et al. Final results of a phase 2 open label, monotherapy efficacy and safety study of quizartinib(AC220) in patients~60 years of age with FLT3- ITD positive or negtive relapsed/refractory acute myeloid leukemia[C]. ASH Annual Meeting Abstracts, 2012,120(21) Abstract 48.
  • 7Schiller GJ,Tallman MS,Goldberg SL,et al. Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia [J]. J Clin Oneol, 2014,32 : 5s(Suppl). Abstract 7100.
  • 8Randhawa JK, Kantarjian HM, Borthakur G, et al. Results of phase lI study of Crenolanib in relapsed/refractory acute myeloid leukemia patients with activating FLT3 mutations[J]. Blood, 2014,124 (21) ; 389.
  • 9Levis MJ, Pearl AE, Altman JK, et al. Results of a first-in- human, phase I/l] trial of ASP-2215, a selective, potent inhibitor of FLT3/AXL in patients with relapsed or refractory (R/R) acute myeloid leukemia(AML) [J]. J Clin Oneol, 2015, 33(Suppl). Abstract 7003.
  • 10Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation[J]. Nature, 2012,483 ( 7390) : 474-478.

同被引文献12

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部